EHA Library - The official digital education library of European Hematology Association (EHA)

THE EFFECT OF COMPLEMENT INHIBITOR CP40 ON ERYTHROCYTE DESTRUCTION IN AIHA
Author(s): ,
Inge Baas
Affiliations:
Department of Immunopathology,Sanquin,Amsterdam,Netherlands
,
Peter Ligthart
Affiliations:
Sanquin Diagnostic Services,Sanquin,Amsterdam,Netherlands
,
Conny Brouwer
Affiliations:
Sanquin Diagnostic Services,Sanquin,Amsterdam,Netherlands
,
Claudia Folman
Affiliations:
Sanquin Diagnostic Services,Sanquin,Amsterdam,Netherlands
,
Edimara Reis
Affiliations:
Department of Pathology and Laboratory Medicine,University of Pennsylvania,Philadelphia,United States
,
Daniel Ricklin
Affiliations:
Department of Pathology and Laboratory Medicine,University of Pennsylvania,Philadelphia,United States
,
John Lambris
Affiliations:
Department of Pathology and Laboratory Medicine,University of Pennsylvania,Philadelphia,United States
,
Diana Wouters
Affiliations:
Department of Immunopathology,Sanquin,Amsterdam,Netherlands
,
Masja de Haas
Affiliations:
Sanquin Diagnostic Services,Sanquin,Amsterdam,Netherlands
Sacha Zeerleder
Affiliations:
Department of Hematology,Academic Medical Center,Amsterdam,Netherlands;Department of Immunopathology,Sanquin,Amsterdam,Netherlands
(Abstract release date: 05/17/18) EHA Library. Baas I. 06/17/18; 214625; S1586
Inge Baas
Inge Baas
Contributions
Abstract

Abstract: S1586

Type: Oral Presentation

Presentation during EHA23: On Sunday, June 17, 2018 from 08:15 - 08:30

Location: Room A9

Background
Autoimmune hemolytic anemia (AIHA) is a rare disease characterized by autoantibodies against erythrocytes. These autoantibodies may activate the classical complement pathway leading to opsonization by complement proteins C3b and C4b. This results in increased clearance of erythrocytes by phagocytes, called extravascular hemolysis. Occasionally, complement activation results in formation of the membrane attack complex (MAC), causing intravascular hemolysis. C3-inhibitor compstatin inhibits C3 activation and thus it is expected to reduce both, C3b deposition as well as well as formation of the MAC. Therefore, compstatin is a potentially efficient inhibitor of extra- and intravascular hemolysis in AIHA. 

Aims
The current aim of this research is to investigate in vitro whether compstatin would be a suitable drug for AIHA treatment. 

Methods
Healthy donor erythrocytes treated with bromelin were incubated with AIHA patient serum together with anti-C5 so that opsonization could be analyzed by FACS using anti-C3-FITC and anti-C4-APC antibodies. In the absence of eculizumab, hemolysis of RBCs was tested by measuring the extinction at 412/690 nm. The percentage hemolysis was calculated relative to the 100% water control. To assess the effect of compstatin cp40 on uptake of erythrocytes by phagocytes, erythrocytes were fluorescently labeled with PKH26 before opsonization. Monocytes isolated by leukapheresis were cultured for 8 or 9 days in the presence of 10 ng/mL GM-CSF to obtain M1-like macrophages or 50 ng/mL M-CSF to obtain M2-like macrophages. Opsonized erythrocytes were then incubated with healthy monocyte derived macrophages and phagocytosis of erythrocytes was measured with ImageStream after lysing the non-phagocytosed erythrocytes.

Results
Complement deposition and MAC formation was induced by AIHA serum via the classical pathway of complement, while this activation was efficiently inhibited by EDTA and other inhibitors, e.g. C1-inhibitors. In these systems, it was shown that compstatin completely inhibited C3 deposition on erythrocytes, while unexpectedly C4 deposition appeared to be increased. Regardless of the increase in C4, compstatin prevented formation of the MAC and RBC lysis. In addition, compstatin inhibited complement-mediated phagocytosis of erythrocytes by M1 macrophages while the effect on phagocytosis by M2 macrophages was less pronounced. When erythrocytes opsonized with both complement and IgG phagocytosis inhibition with compstatin was less efficient as compared to the inhibition of phagocytosis of erythrocytes opsonized with complement only. 

Conclusion
We demonstrate that compstatin inhibits C3b deposition, C3-mediated phagocytosis of opsonized RBCs as well as MAC formation. Therefore, compstatin is a potential candidate for therapeutical application in AIHA patients to inhibit both intra- and extravascular hemolysis.  

Session topic: 32. Transfusion medicine

Keyword(s): AIHA (see autoimmune hemolytic anemia), Complement, transfusion

Abstract: S1586

Type: Oral Presentation

Presentation during EHA23: On Sunday, June 17, 2018 from 08:15 - 08:30

Location: Room A9

Background
Autoimmune hemolytic anemia (AIHA) is a rare disease characterized by autoantibodies against erythrocytes. These autoantibodies may activate the classical complement pathway leading to opsonization by complement proteins C3b and C4b. This results in increased clearance of erythrocytes by phagocytes, called extravascular hemolysis. Occasionally, complement activation results in formation of the membrane attack complex (MAC), causing intravascular hemolysis. C3-inhibitor compstatin inhibits C3 activation and thus it is expected to reduce both, C3b deposition as well as well as formation of the MAC. Therefore, compstatin is a potentially efficient inhibitor of extra- and intravascular hemolysis in AIHA. 

Aims
The current aim of this research is to investigate in vitro whether compstatin would be a suitable drug for AIHA treatment. 

Methods
Healthy donor erythrocytes treated with bromelin were incubated with AIHA patient serum together with anti-C5 so that opsonization could be analyzed by FACS using anti-C3-FITC and anti-C4-APC antibodies. In the absence of eculizumab, hemolysis of RBCs was tested by measuring the extinction at 412/690 nm. The percentage hemolysis was calculated relative to the 100% water control. To assess the effect of compstatin cp40 on uptake of erythrocytes by phagocytes, erythrocytes were fluorescently labeled with PKH26 before opsonization. Monocytes isolated by leukapheresis were cultured for 8 or 9 days in the presence of 10 ng/mL GM-CSF to obtain M1-like macrophages or 50 ng/mL M-CSF to obtain M2-like macrophages. Opsonized erythrocytes were then incubated with healthy monocyte derived macrophages and phagocytosis of erythrocytes was measured with ImageStream after lysing the non-phagocytosed erythrocytes.

Results
Complement deposition and MAC formation was induced by AIHA serum via the classical pathway of complement, while this activation was efficiently inhibited by EDTA and other inhibitors, e.g. C1-inhibitors. In these systems, it was shown that compstatin completely inhibited C3 deposition on erythrocytes, while unexpectedly C4 deposition appeared to be increased. Regardless of the increase in C4, compstatin prevented formation of the MAC and RBC lysis. In addition, compstatin inhibited complement-mediated phagocytosis of erythrocytes by M1 macrophages while the effect on phagocytosis by M2 macrophages was less pronounced. When erythrocytes opsonized with both complement and IgG phagocytosis inhibition with compstatin was less efficient as compared to the inhibition of phagocytosis of erythrocytes opsonized with complement only. 

Conclusion
We demonstrate that compstatin inhibits C3b deposition, C3-mediated phagocytosis of opsonized RBCs as well as MAC formation. Therefore, compstatin is a potential candidate for therapeutical application in AIHA patients to inhibit both intra- and extravascular hemolysis.  

Session topic: 32. Transfusion medicine

Keyword(s): AIHA (see autoimmune hemolytic anemia), Complement, transfusion

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies